TUC-S.R.L.
Just over a month after the Digital World Premiere, TUC.tiny is ready to make its debut at VivaTech 2024, the most important technology fair in Europe. In Hall 1, Pavilion 41, TUC S.r.l. will present to the public for the first time its latest technological innovation: TUC.tiny®, the Modular Dashboard concept, and the TUC.technology offering, developed to revolutionize the world of mobility.
TUC.tiny® is the compact version of the industrialized technology launched last year, based on the TUC.technology® patent and released in over 140 countries. It is currently the subject of collaborations with industry leaders such as ZER01NE, the Hyundai Motor Group's Open Innovation Platform, for the development of "Human-centric" vehicles.
This technological gem is based on the three pillars of TUC: mechanical structure, electronic management, and data exchange. Thanks to the integration of USB Type-C technology, TUC.tiny® aims to reinvent the interaction between users and vehicles, converging mobility and everyday life.
The result of advanced research by TUC S.r.l. in technological miniaturization and simplification, TUC.tiny® represents the core of the company's patented technology, designed to innovate the value chain in the mobility sector with a "human-centric" approach. It is an ideal solution for both the main players in the sector and users, representing a perfect synthesis of their needs.
The Modular Dashboard, developed to showcase the potential of TUC.tiny®, is a true blank canvas, customizable infinite times thanks to TUC.tiny® and TUC.technology®. An environment to inhabit and configure without limits, adapting functionally and flexibly to the needs of users.
With TUC.tiny® and its advanced interface - including physical fastening, electrical connectivity, and data transfer - any device can be integrated into the modular dashboard design, making it immediately operational. TUC.tiny® supports all everyday devices with USB Type-C connection, distinguishing itself by seamlessly blending into any part of the vehicle. Its robustness is ensured by a mechanical or electro-actuated locking mechanism, introducing the novelty of NFC technology for added security.
The introduction of TUC.tiny® completes the TUC.technology® offering, marking a step forward towards the democratization of technology. The gateway to an advanced mobility experience becomes wider, easily accommodating the smart objects that animate our daily lives.
TUC.tiny® and TUC.technology® embody the vision of the mobility ecosystem of the future: interconnected, multimodal, circular, and dynamic. This technology not only connects but synthesizes different spheres of our lives, making mobility more accessible, customizable, and environmentally conscious.
TUC invites everyone to imagine and build together a world where technology unites us, improving every aspect of our daily journey. The project, which started in the automotive sector, now aims to scale the technology to new verticals such as aerospace and marine sectors.
“The World Premiere of TUC.tiny® at VivaTech 2024 is an important recognition for TUC.technology as an enabler of the Mobility of the Future," said Ludovico Campana, Inventor and CEO of TUC. “TUC.tiny® represents our promise for the future: the vision of a world where technology and mobility create personalized experiences designed around the needs of each individual. This is the future that TUC S.r.l. is building: a mobility ecosystem driven by the values of democratization, personalization, and sustainability."
TUC.tiny® and the Modular Dashboard are ready to be showcased live to the public at VivaTech 2024, demonstrating that this vision is already a reality.
For more information, visit the "NEWSROOM" section of the website: https://www.tuc.technology/newsroom.
ABOUT TUC.technology
TUC S.r.l. is a leading Deep-Tech company in mobility innovation, specializing in the development of modular solutions for vehicles that aim to simplify and revolutionize the concept of a vehicle. Distinguished by technological excellence on an international level, TUC has received significant recognitions, including exhibitions at CES in Las Vegas and the National Automobile Museum.
With the launch of TUC 3.0, the company sets new standards in the sector, collaborating with major global OEMs. Learn more at http://www.tuc.technology.
Facebook @TUCtechnology
Instagram @tuc.technology
Twitter @TUCtechnology
Linkedin @TUC.technology
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240515972855/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom